TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a man or a woman aged 18 to 55 years of age.~* Subject has chronic Hepatitis C~* Subject is willing to not use alcohol for 2 weeks prior to therapy and through the study follow-up period~Exclusion Criteria:~* Patient has evidence of advanced liver disease.~* Patient has human immunodeficiency virus (HIV)~* Patient has Hepatitis B

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 25 mg b.i.d. MK7009
- 2 (Type: EXPERIMENTAL): 75 mg b.i.d. MK7009
- 3 (Type: EXPERIMENTAL): 250 mg b.i.d. MK7009
- 4 (Type: EXPERIMENTAL): 500 mg b.i.d. MK7009
- 5 (Type: EXPERIMENTAL): 700 mg b.i.d. MK7009
- 6 (Type: EXPERIMENTAL): 125 mg q.d. MK7009
- 7 (Type: EXPERIMENTAL): 600 mg q.d. MK7009
- 8 (Type: EXPERIMENTAL): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pegaferon and Ribavirin for Hepatitis C

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C~* Age between 15 and 65~Exclusion Criteria:~* previous treatment for chronic hepatitis C~* co-infection with human immunodeficiency virus or hepatitis B virus~* major thalassemia or hemophilia~* active drug user~* being treated for major depression or psychosis~* decompensated cirrhosis~* serum creatinine \> 1.5 mg/dL~* solid organ transplant~* untreated thyroid disease~* uncontrolled diabetes mellitus~* uncontrolled autoimmune disease~* advanced cardiac or pulmonary disease.~* planning to become pregnant in the next 1.5 years~* patients with inadequate contraception~* not consenting to the study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Histological diagnosis of Diffuse Large B Cell Lymphoma (de novo or transformed) expressing CD19 by immunohistochemistry or flow cytometry analysis (\>30% positivity), based on recent (less than 6 months) or new biopsy.~* At least 1 prior specific therapeutic regimen, one of which should have included rituximab (patients previously eligible for transplantation: the salvage treatment followed by intensification and Autologous Stem Cell Transplant (ASCT) will be considered one regimen).~* Relapsed disease after standard 1st line therapy for aggressive lymphoma - not eligible for high dose chemotherapy with stem cell support. Relapsed or refractory disease after two lines of therapy one of which could have included Autologous Stem Cell Transplant (ASCT). Relapsed disease is defined as progression after a disease free interval of at least 6 months after completion of last therapy. Refractory is defined as progression of disease during prior therapy or within 6 months from its completion.~* Available paraffin-embedded tissue should have been collected no longer than 6 months prior to first administration of SAR3419. Cryo-preserved tissue cannot be used. If archival material is not available, a Fine Needle Aspiration (FNA) must be obtained.~Exclusion criteria:~* Primary refractory patients~* Patients with primary mediastinal DLBCL~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAR3419 (Type: EXPERIMENTAL): All patients will receive SAR3419 until evidence of disease progression, unacceptable toxicity, or other reasons for therapy discontinuation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Minimally Invasive Sensing of Beta-lactam Antibiotics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult \>18 years old~* Healthy with no evidence of active infection~* Previously received penicillin with no adverse effects~Exclusion Criteria:~* High risk of skin soft tissue infection or local skin and soft tissue infection near sensor site~* Previous history of allergies to adhesive strips or active dermatitis~* Penicillin allergy or previous adverse event whilst receiving penicillin~* Anaemia on screening bloods (defined as haemoglobin \<13 g/dL in males and \<12 g/dL in females)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy volunteer (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: the Effect of Dopamine on Mechanical Ventilation Induced Lung Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients inclusion criteria: undergo elective lobectomy with general anesthesia and mechanical ventilation; classified as physical status I to III according to the American Society of Anesthesiologists Physical Status Classification System; Written informed consent is approved.~Exclusion Criteria:~* Distant metastases: recent anaesthetics or mechanical ventilation treatment；children；women during pregnancy or lactation; being involved in other clinical subjects.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ventilation (Type: None): patients undergoing selective operation with general anesthesia(GA) and mechanical ventilation(MV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of written patient informed consent.~2. Patients must have a smart phone at their disposal and use it on a daily basis.~3. Female or male aged \>18 years, diagnosed with a ST elevation Myocardial Infarction (STEMI) or non ST elevation Myocardial Infarction (NSTEMI) and treated with ticagrelor prior to inclusion into this study and for which the treating physician intend to continue prescribing ticagrelor according to the prescription recommendation.~4. Ability to read, understand and write Swedish.~Exclusion Criteria:~1. Participation in any clinical trial or device study in the last 30 days excluding prospective/retrospective register based studies that do not require any extra visits in addition to ordinary health care.~2. Patients not suitable for participation based on the investigators judgment for example:~   * Patients on treatment with triple antithrombotic treatment.~  * Patients on treatment with anticoagulantia.~  * Patients accepted/with a plan for thoracic surgery (CABG) or any other elective surgery that cannot be postponed until after study participation.~  * Patients with a life expectancy of less than 12 months.~  * Patients judged to be unable to follow a structured physical activity program.~3. Patients those are pregnant or lactating.~4. Patients involved in the planning and/or conduct of the study (applies to AstraZeneca staff and/or staff at the study site and application developer).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active group (Type: EXPERIMENTAL): The software application used on the patients' smart phones in the active group, will contain both the e-diary and the mobile-phone based patient support. Patients will receive feedback by the mobile-phone based support not only on the data they enter into the mobile-phone based patient support but also on their reported daily ticagrelor use.
- The control group (Type: PLACEBO_COMPARATOR): In this group the patients will have access to the e-diary only, in which they will report their daily use of ticagrelor. The patients in the control group will not receive any feed-back.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antithrombotic Effects of Ticagrelor Versus Clopidogrel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female volunteers between 18 and 65 years old.~* Body mass index (BMI) 18 - 30 kg/m2 inclusive.~* Healthy as assessed by a detailed medical history and physical examination.~* Laboratory est results within the normal range.~* Ability to provide signed informed consent.~Exclusion Criteria:~* History of clinically relevant disease, bleeding, acute infectious disease or signs of acute illness.~* Allergy or hypersensitivity to aspirin or thienopyridines, or atopy diagnosed by a physician.~* Use of medication within one month prior to study drug administration.~* History of drug abuse or alcohol consumption \>20 g/day.~* Inability to abstain from intensive muscular effort or sport competition.~* Loss of \>400 mL blood or blood donation within 3 months.~* Positive serology for hepatitis B (HBs Ag) or hepatitis C.~* Conditions associated with hemorrhagic risk.~* Positive pregnancy test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Ticagrelor + ASA + Bivalirudin (Type: EXPERIMENTAL): Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
- Clopidogrel + ASA + Bivalirudin (Type: ACTIVE_COMPARATOR): Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be \>18 years of age at the time of signing the informed consent form~* MDS at IPSS Int-2 or High with a karyotype including del(5q) or monosomy 5 confirmed with FISH (using the LSI EGR1/D5S23,D5S721 FISH probe)~* Acute myeloid leukemia with a karyotype including del(5q) or monosomy 5 confirmed with FISH (using the LSI EGR1/D5S23,D5S721 FISH probe)~* Patients could be included if:~* At diagnosis and not considered eligible for induction chemotherapy~* Refractory to induction therapy~* Relapse after induction chemotherapy leading to CR and considered not eligible for reinduction~* Relapse after allogeneic stem cell transplantation and not considered suitable for reinduction chemotherapy or other conventional relapse therapy.~* Subject has signed the informed consent document.~* Women of childbearing potential, WCBP, must agree to practice complete abstinence from heterosexual intercourse or to use two methods of contraception beginning 4 weeks prior to the start of the study medication, while on study medication and 4 weeks after the last dose of study medication. WCBP must have two negative serum or urine pregnancy tests prior to starting study drug. WCBP must agree to have pregnancy tests weekly for the first 4 weeks and then every 4 weeks while on study medication and 4 weeks after the last dose of study medication.~* Males (including those who have had a vasectomy) must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with WCBP while on study medication and 4 weeks after the last dose of study medication.~Exclusion Criteria:~* Pregnant or lactating females.~* Prior therapy with lenalidomide~* Patients who are eligible for curative treatment~* Expected survival less than two months.~* Acute promyelocytic leukemia (APL)~* Absolute peripheral blast count \>30,000/mm3~* Central nervous system leukemia~* Serum biochemical values as follows~* Serum creatinine \>2.0 mg/dL (177 micromol/L)~* Serum aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) \>3.0 x upper limit of normal (ULN)~* Serum total bilirubin \>1.5 mg/dL (26 micromol/L)~* Prior allergic reaction to thalidomide~* Uncontrolled systemic infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1. lenalidomide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Crohns Disease for at least 6 weeks~* Moderate to severe disease activity (CDAI \>= 220 and \<=450)~* No history of azathioprine, 6-MP (6 Mercaptopurine), or biologic treatments~* Are either: Corticosteriod-dependent, OR considered for a 2nd (or greater) course of corticosteriod, OR 5-ASA failures, Or Budesonide failures~Exclusion Criteria:~* History of abdominal surgery within the last 6 months~* Have an ostomy or stoma \[An operation to create an opening from an area inside the body to the outside\]~* Are pregnant, nursing, or planning pregnancy (both men and women)~* Serious simultaneous illness that could interfere with study participation~* Use of any investigational drug within 30 days~* Have a concomitant diagnosis or any history of congestive heart failure~* Weigh more than 140 kilograms (or 310 pounds)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 003 (Type: EXPERIMENTAL): infliximab (IFX) infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
- 001 (Type: EXPERIMENTAL): infliximab (IFX) placebo infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
- 002 (Type: EXPERIMENTAL): infliximab infusion; AZA placebo caps Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* dialysis patients (\>3 months)~Exclusion Criteria:~* diabetics~* hospital stay in the last 4 weeks

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male, aged 18-70 years (both inclusive) at the time of signing informed consent~* Patients with the diagnosis of congenital haemophilia B with factor IX activity below or equal to 2%, based on medical records~* History of more than 150 exposures days to any factor IX containing products~Exclusion Criteria:~* Known history of factor IX inhibitors~* Inhibitors to factor IX (above or equal to 0.6 BU) at screening measured by the Nijmegen modified Bethesda method~* Immunocompromised (CD4+ T cells below or equal to 200/μL)~* Known congenital or acquired coagulation disorders other than haemophilia B~* Body mass index above 35 kg/m\^²

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- N9-GP (Type: EXPERIMENTAL): None
- ALPROLIX® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed\* acute anterior wall myocardial infarction (ST segment elevation ≥ 2mm in ≥ 2 contiguous leads \[one of which should be V2, V3, or V4\]).~2. Killip class I or II on diagnosis.~   * Cases of non-confirmed infarction by enzymatic release (above 2 standard deviations from upper limit of CK and Troponin) are excluded from efficacy analysis but kept in the safety analysis.~Exclusion Criteria:~1. COPD or asthma on active bronchodilator therapy~2. Active treatment with beta blockers~3. Left bundle branch block or pacemaker.~4. Systolic blood pressure \<120 mmHg, Heart rate \<60 bpm, or AV block (PR˃240 mS or superior) on diagnosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Early metoprolol initiation strategy (Type: ACTIVE_COMPARATOR): None
- Delayed metoprolol initiation strategy (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus Conversions in African-American Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age and able to give informed consent~* African-American ethnicity~* Received a first or second non-ECD cadaveric or living donor renal transplant~* Transplant occurred during the past 6 to 24 weeks~* Patient has stable graft function, defined as no change of greater than 30% of baseline serum creatinine during the past month and no acute rejection in the past 6 weeks~* Estimated GFR using the modified MDRD equation of at least 40 mL/min10 at time of enrollment into the study~* Currently receiving tacrolimus, mycophenolate mofetil (at least 1 gm per day), and corticosteroids as their immunosuppression regimen.~Exclusion Criteria:~* Biopsy proven acute rejection episode that occurred within the past 6 weeks~* Malignancy within the past 3 years, except for non-melanoma skin cancer~* Any known intolerances to current immunosuppressant regimen necessitating withdrawal of the offending agent~* Currently enrolled in an investigational trial~* Woman of child bearing potential not utilizing an effective form of birth control~* Patients with uncontrolled dyslipidemia, defined at serum fasting LDL \>200 mg/dL or serum fasting triglycerides \>500 mg/dL.~* Patients with a spot urine protein to creatinine ratio of \> 800 mg of protein per gram of creatinine.~* WBC \< 3,000 cells/mm3~* Platelets \< 100,000 cells/mm3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus Withdrawal Arm (Type: ACTIVE_COMPARATOR): At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator.
- Tacrolimus Minimization Arm (Type: ACTIVE_COMPARATOR): Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete